, Singapore
146 views
Photo from Envato Elements

IFA deems Cordlife's partial offer not fair and not reasonable

Medeze Treasury proposed to acquire 25.63 million shares in Cordlife at $0.25 each.

Novus Corporate Finance, the appointed independent financial advisor (IFA) to oversee the partial offer made by Medeze Treasury, to acquire a 10.00% stake in Cordlife Group has deemed the offer “not fair and not reasonable”.

On May 13, Medeze Treasury proposed to acquire 25.63 million shares in Cordlife at $0.25 per share. Medeze Treasury currently holds a 0.68% stake in the company.

The offer price represents a discount of approximately 22.4% and 22.8% to the volume-weighted average price (VWAP) of the shares for the three-year and two-year periods prior to and including the last trading day, respectively.

In respect of comparable companies, Cordlife recorded a net loss attributable to equity holders of the company and a negative EBITDA for FY2024.

In addition, the company’s price to net asset values (P/NAV) ratio of 0.54 times is below the range as well as the mean and median P/NAV ratios of the comparable companies.

As a result, the IFA recommends rejecting the partial offer.

Join Singapore Business Review community

Follow the link for more news on

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.